HER2 Negative Breast Carcinoma trials recruiting in Massachusetts

All HER2 Negative Breast Carcinoma trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Beverly, Boston, Burlington, Gloucester
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
  NCT06042569 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Burlington
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
  NCT04150042 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston